Vaxart Announces Corporate Update for First Quarter 2020
Vaxart, Inc. (VXRT)
Last vaxart, inc. earnings: 3/19 04:01 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Preparations for the Manufacturing of GMP Vaccine at Emergent BioSolutions Ongoing Vaxart is Participating in Maxim’s Infectious Disease Virtual Conference on May 5, 2020 SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today provided an update on its financials for the first quarter of 2020, and a corporate update ahead of its presentation at the Maxim Infectious Disease Virtual Conference on May 5, 2020. “This has been a busy quarter at Vaxart, as we have focused on developing a vaccine candidate for COVID-19,” said Wouter Latour, MD, chief executive officer of Vaxart Inc. “We believe our oral tablet vaccine could be an important tool to help protect the global population from COVID-19.” 2020 Q1 Financials Update and Recent Corporate Highlights: Vaxart had cash of $29.9 million as of March 31, 2
Show less
Read more
Impact Snapshot
Event Time:
VXRT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VXRT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VXRT alerts
High impacting Vaxart, Inc. news events
Weekly update
A roundup of the hottest topics
VXRT
News
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Vaxart Provides Business Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13GlobeNewswire
- Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024GlobeNewswire
- Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet NeedGlobeNewswire
VXRT
Earnings
- 11/13/24 - Beat
VXRT
Sec Filings
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- 10/8/24 - Form 424B5
- VXRT's page on the SEC website